Atrial Fibrillation

Featured Article

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.

Latest News

Troponin-T, NT-proBNP May Predict Mortality Risk in Atrial Fibrillation

Troponin-T, NT-proBNP May Predict Mortality Risk in Atrial Fibrillation

Troponin-T, N-terminal pro-B-type natriuretic peptide, and growth differentiation factor-15 may offer prognostic utility on mortality and bleeding events in patients with atrial fibrillation who receive anticoagulation.

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

A greater burden of atrial fibrillation or flutter in patients with paroxysmal atrial fibrillation was associated with a higher risk for stroke when not taking anticoagulants.

COPD May Increase the Risk for Atrial Fibrillation

COPD May Increase the Risk for Atrial Fibrillation

Patients with COPD had a nearly 2-fold increased risk for developing atrial fibrillation compared with patients without COPD.

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.

Afib Risk Not Affected by Borderline ABI in Peripheral Artery Disease

Afib Risk Not Affected by Borderline ABI in Peripheral Artery Disease

Peripheral artery disease with a borderline ankle-branchial index appears not to increase the risk for atrial fibrillation.

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

Anxiety may increase the risk for ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation.

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Latest Features

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

Atrial Fibrillation: Updates in Screening, Surgical Ablation, and Anticoagulation Use

Atrial Fibrillation: Updates in Screening, Surgical Ablation, and Anticoagulation Use

Anticoagulation under- and overdoing can be problematic in patients with atrial fibrillation.

Weighing Benefits and Risks of Anticoagulation in the Elderly

Weighing Benefits and Risks of Anticoagulation in the Elderly

Determining which patients who have atrial fibrillation should receive anticoagulation therapy for stroke prophylaxis can be challenging.

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

A declining trend in ischemic events was associated with oral anticoagulant therapy after intracranial hemorrhage.

ACC/AHA Issue Revised Performance and Quality Measures for Atrial Fibrillation

ACC/AHA Issue Revised Performance and Quality Measures for Atrial Fibrillation

New ACC/AHA performance and quality measures for atrial fibrillation/flutter include metrics for outpatient care.

Cryoablation vs Radiofrequency Ablation in Atrial Fibrillation

Cryoablation vs Radiofrequency Ablation in Atrial Fibrillation

Experts weigh in on cryoablation vs radiofrequency ablation techniques for atrial fibrillation in light of FIRE and ICE trial results.

Left Atrial Appendage Closure: Exciting New Proposition or a Practically Non-Feasible Alternative?

Left Atrial Appendage Closure: Exciting New Proposition or a Practically Non-Feasible Alternative?

Occlusion of the left atrial appendage provides protection against thromboembolic stroke in patients with nonvalvular atrial fibrillation.

Factors Affecting Choice of Non-Vitamin K Antagonist Oral Anticoagulants

Factors Affecting Choice of Non-Vitamin K Antagonist Oral Anticoagulants

Choosing the right anticoagulant agent can be a challenge for many reasons, including cost, familiarity, drug interactions, and reversibility.

Sign Up for Free e-Newsletters